Studies how well rimegepant works for migraine attacks and how well it is tolerated
Studies rimegepant, a tablet for migraine attacks, in adults with migraine.
Plain-language title generated from the registry record
Registry title: Gepant treAtments: EffectIveNess and tolERability (GAINER)
Key facts
- Where
- Florence and Pavia, ItalySee the 2 sites
Where in Italy
- SOD Centro Cefalee e Farmacologia Clinica, AOU CareggiFlorence, ItalyTaking people
- IRCCS National Neurological Institute "C. Mondino" FoundationPavia, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Florence
- Trial code
- NCT05903027
- Record updated
- 21 January 2026
- Original description
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.Read full original descriptionShow less
Effectiveness and Tolerability of Rimegepant as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study (GAINER)
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
Inclusion: Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III); At least 3 MMDs; Good compliance to study procedures; Availability of headache diary at least of the preceding months before enrollment.
Exclusion: Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments; Subjects with contraindications for use of gepants; medical comorbidities that could interfere with study results; Pregnancy and breastfeeding.